QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neuroone-medical-technologies-reports-preliminary-fy25-results-of-91m-product-revenue-and-66m-cash-on-hand

 Preliminary Results On October 6, 2024, the Company reported the following preliminary unaudited fiscal year 2025 financial an...

 maxim-group-initiates-coverage-on-neuroone-medical-tech-with-buy-rating-announces-price-target-of-3

Maxim Group analyst Anthony Vendetti initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announc...

 neuroone-medical-technologies--files-prospectus-for-675m-share-sale

-SEC Filing

 neuroone-medical-tech-affirms-fy2025-sales-guidance-of-800m-1000m-vs-871m-est

NeuroOne Medical Tech (NASDAQ:NMTC) affirms FY2025 sales outlook from $8.00 million-$10.00 million to $8.00 million-$10.00 mill...

 neuroone-medical-tech-q3-eps-003-beats-005-estimate-sales-170m-miss-182m-estimate

NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of...

 neuroone-medical-technologies-patient-treated-with-patented-onerf-ablation-system-surpasses-one-year-milestone-of-being-seizure-free

Patient Treated with OneRF® Ablation System Previously Experienced up to 10 Seizures a DayEDEN PRAIRIE, Minn., June 23, 2025 (G...

 neuroone-medical-tech-affirms-fy2025-product-revenue-guidance-of-800m-1000m

NeuroOne Medical Tech (NASDAQ:NMTC) affirms FY2025 sales outlook from $8.00 million-$10.00 million to $8.00 million-$10.00 mill...

 neuroone-medical-tech-q2-eps-007-up-from-011-yoy-sales-139m-beat-127m-estimate

NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.07) per share. This is a 36.36 percent increase over losse...

 ladenburg-thalmann-initiates-coverage-on-neuroone-medical-tech-with-buy-rating-announces-price-target-of-145

Ladenburg Thalmann analyst Jeff Cohen initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announ...

 neuroone-medical-technologies-files-510k-submission-to-fda-for-trigeminal-nerve-ablation-earlier-than-anticipated

Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical TreatmentsSubmission Completed Earlier Than An...

 neuroone-issues-letter-to-shareholders-reiterating-fy25-guidance-with-product-revenues-expected-to-increase-to-between-8m-10m-representing-an-increase-of-between-132-to-190-when-compared-to-product-revenue-of-35m-in-fy24

Today, we stand as a larger, more mature company than ever before as we ramp revenues and product margins. We have a world clas...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION